Wedbush Issues Optimistic Estimate for Immunome Earnings

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at Wedbush upped their Q1 2025 EPS estimates for Immunome in a research report issued on Wednesday, March 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.72). Wedbush has a "Outperform" rating and a $33.00 price objective on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome's Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.80) EPS and FY2027 earnings at ($1.35) EPS.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million for the quarter, compared to analysts' expectations of $3.07 million.

Several other equities research analysts have also recently issued reports on the stock. Lifesci Capital assumed coverage on shares of Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective for the company. Stephens reiterated an "overweight" rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Guggenheim dropped their price objective on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $25.50.

Immunome Trading Up 2.7 %

Shares of IMNM traded up $0.19 during trading hours on Monday, reaching $7.28. 1,219,389 shares of the company traded hands, compared to its average volume of 840,055. The stock's fifty day moving average price is $9.61 and its 200 day moving average price is $11.41. The firm has a market cap of $633.00 million, a price-to-earnings ratio of -0.90 and a beta of 1.93. Immunome has a 12-month low of $6.94 and a 12-month high of $26.70.

Insider Transactions at Immunome

In related news, Director Jean Jacques Bienaime bought 7,000 shares of the business's stock in a transaction on Monday, March 24th. The shares were bought at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares of the company's stock, valued at approximately $193,879.15. This trade represents a 42.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Clay B. Siegall purchased 150,000 shares of the firm's stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares of the company's stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 306,400 shares of company stock valued at $2,322,995. Company insiders own 8.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in Immunome in the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome in the 4th quarter worth $75,000. AlphaQuest LLC grew its stake in Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after buying an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after buying an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in Immunome during the 4th quarter valued at about $95,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.